DrugBiological
Olaratumab clinical trials
Also written LY3012207 and IMC-3G3.
- studies test it
- 17
- open now
- 0
- in phase 3
- 1
- first study started
- 2006
How studies write it
Studies that test it under each name
Name
Brand
Combined with it in one product
Studies by the year they started
17 studies that test it; most in 2010 (5)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2009 | 1 |
| 2010 | 5 |
| 2011 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 9
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 4
Eli Lilly and Company (13) · Grupo Espanol de Investigacion en Sarcomas (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · University of Miami (1)
Often tested with
Tested in the same studies.
Doxorubicin (5) · Trabectedin (2) · Pembrolizumab (1) · Ifosfamide (1) · Liposomal doxorubicin (1) · Ramucirumab (1) · Dexrazoxane (1)
Studies
Open first, then newest update. How each study uses olaratumab is read from its arms, and is right about nine times in ten.
Testing it · 17
- A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue SarcomaCompletedPhase 3Eli Lilly and CompanyNCT02451943Written as Olaratumab
- A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue SarcomaCompletedPhase 1Eli Lilly and CompanyNCT03126591Written as Olaratumab
- Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma PatientsActive, not recruitingPhase 1Grupo Espanol de Investigacion en SarcomasNCT03985722Written as Olaratumab and Trabectedin
- A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic CancerCompletedPhase 1/2Eli Lilly and CompanyNCT03086369Written as Olaratumab
- A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue SarcomaCompletedPhase 1/2Eli Lilly and CompanyNCT02659020Written as Olaratumab
- A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue SarcomaCompletedPhase 1Eli Lilly and CompanyNCT03283696Written as Olaratumab
- OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma PatientsTerminatedPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT03698227Written as Olaratumab
- A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue SarcomaCompletedPhase 1Eli Lilly and CompanyNCT02326025Written as Olaratumab
- A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian CancerCompletedPhase 2Eli Lilly and CompanyNCT00913835Written as Olaratumab
- A Study of Olaratumab (IMC-3G3) in Prostate CancerCompletedPhase 2Eli Lilly and CompanyNCT01204710Written as Olaratumab
- Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent LeiomyosarcomaWithdrawnPhase 1University of MiamiNCT03437070Written as Olaratumab
- A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 2Eli Lilly and CompanyNCT00918203Written as Olaratumab
- Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT00895180Written as olaratumab
- Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid TumorsCompletedPhase 1Eli Lilly and CompanyNCT01199822Written as Olaratumab
- A Study of Olaratumab in Soft Tissue SarcomaCompletedPhase 1/2Eli Lilly and CompanyNCT01185964Written as Olaratumab
- A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal TumorsTerminatedPhase 2Eli Lilly and CompanyNCT01316263Written as Olaratumab
- Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is AvailableCompletedPhase 1Eli Lilly and CompanyNCT00768391Written as IMC-3G3
Given in every arm · 3 — olaratumab is usual care beside what is tested
- A Study of Olaratumab in Japanese Participants With Advanced CancerCompletedPhase 1Eli Lilly and CompanyNCT02377752Written as Olaratumab
- A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With CancerCompletedPhase 1Eli Lilly and CompanyNCT02677116Written as Olaratumab
- A Study of Olaratumab (LY3012207) in Participants With Soft Tissue SarcomaCompletedPhase 1Eli Lilly and CompanyNCT02783599Written as Olaratumab
Codes
What other systems call olaratumab · ClinicalTrials.gg INT000029
- MeSH (NLM) C000589393olaratumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) TT6HN20MVFOLARATUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1855735Confirmed FDA, Wikidata
- Wikidata Q7083108olaratumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C79825OlaratumabOne source FDA
- DrugBank DB06043One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000589393 | olaratumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | TT6HN20MVF | OLARATUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1855735 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7083108 | olaratumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C79825 | Olaratumab | One source FDA |
| DrugBank | DB06043 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.